We are live on
!
Find out more
HVC
Healthcare Value Capital Portfolio holdings
AUM
$50.7M
Turnover
28.57%
1-Year Est. Return
24.72%
This Fund
S&P 500
This Quarter
Est. Return
+1.89%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$50M
AUM Growth
-$5.68M
(-10%)
Cap. Flow
+$9.56M
Cap. Flow
% of AUM
19.14%
Top 10 Holdings %
Top 10 Hldgs %
97.9%
Holding
20
New
3
Increased
2
Reduced
1
Closed
7
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TYME
Tyme Technologies, Inc. Common Stock
TYME
|
+$12.1M |
| 2 |
GSK
GSK
|
+$2.03M |
| 3 |
Assertio
ASRT
|
+$1.18M |
| 4 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
+$401K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$3.65M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$2.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.31% |
| 2 | Miscellaneous | 16.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TYME
1
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $11M | 21.92% |
+2,075,000
| New | +$12.1M |
2017 Q3
0 quarters
|
|
2
Pfizer
PFE
$169B
| $8.93M | 17.86% |
263,500
| – | – |
2014 Q1
14 quarters
|
|
|
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $6.2M | 12.4% |
881,440
+50,000
| +6% | +$401K |
2016 Q4
3 quarters
|
|
4
Gilead Sciences
GILD
$194B
| $6.08M | 12.16% |
75,000
| – | – |
2016 Q3
4 quarters
|
|
|
5
CALL
Gilead Sciences
GILD
$194B
| $4.86M | 9.73% |
60,000
| – | – |
2016 Q3
4 quarters
|
|
|
6
DELISTED
Assertio
ASRT
| $4.05M | 8.11% |
11,667
+2,500
| +27% | +$1.18M |
2015 Q4
7 quarters
|
|
|
7
PUT
DELISTED
Assertio
ASRT
| $2.43M | 4.87% |
+7,000
| New | +$3.3M |
2017 Q3
0 quarters
|
|
|
8
GSK
GSK
$99.2B
| $2.03M | 4.06% |
+40,000
| New | +$2.03M |
2017 Q3
0 quarters
|
|
9
Standard BioTools
LAB
$247M
| $1.82M | 3.64% |
360,500
| – | – |
2017 Q1
2 quarters
|
|
10
Amarin Corp
AMRN
$239M
| $1.57M | 3.15% |
22,500
| – | – |
2016 Q3
4 quarters
|
|
11
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
| $514K | 1.03% |
3,125
| – | – |
2017 Q2
1 quarter
|
|
|
12
CALL
Standard BioTools
LAB
$247M
| $504K | 1.01% |
100,000
-50,000
| -33% | -$210K |
2017 Q1
2 quarters
|
|
|
FCSC
13
CALL
DELISTED
Fibrocell Science Inc.
FCSC
| $31K | 0.06% |
2,000
| – | – |
2017 Q2
1 quarter
|
|
14
PUT
Artivion
AORT
$1.06B
| – | – |
-200,000
| Closed | -$3.99M | – |
|
|
15
CALL
DELISTED
Assertio
ASRT
| – | – |
-1,667
| Closed | -$1.07M | – |
|
|
16
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
| – | – |
-25,000
| Closed | -$4.85M | – |
|
|
17
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
| – | – |
-75,000
| Closed | -$2.49M | – |
|
18
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$241M
| – | – |
-781
| Closed | -$2.66M | – |
|
|
IMMU
19
CALL
DELISTED
Immunomedics Inc
IMMU
| – | – |
-100,000
| Closed | -$883K | – |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| – | – |
-15,000
| Closed | -$3.65M | – |
|
Similar funds
C
CC
FCOI
FCOI
BI
KC
SCIM
MCP
Healthcare Value Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Healthcare Value Capital held 20 positions worth $50M, down 10% from $55.7M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Healthcare Value Capital deployed $9.56M of net new capital in Q3 2017, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was Tyme Technologies, Inc. Common Stock: 2,075,000 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 66% a quarter earlier, followed by Miscellaneous.
On the sell side, the most notable exit was Allergan plc, an estimated $3.65M sold.
- Healthcare Value Capital's largest Q3 2017 buy was Tyme Technologies, Inc. Common Stock: 2,075,000 shares worth $11M.
- Healthcare Value Capital added most to Assertio in Q3 2017, an estimated $1.18M increase.
- Healthcare Value Capital fully exited Allergan plc in Q3 2017, selling an estimated $3.65M.
- Healthcare Value Capital's ten largest holdings make up 98% of its $50M portfolio in Q3 2017.
- Healthcare Value Capital opened 3 new positions and closed 7 in Q3 2017.
- Healthcare Value Capital's portfolio value fell 10% quarter-over-quarter to $50M.
Based on Healthcare Value Capital's 13F filing for Q3 2017, filed 13 Nov 2017.